Apr. 16 at 8:51 PM
Trevi Therapeutics announced a proposed public offering of common stock, targeting
$150 million in gross proceeds. The clinical-stage biopharmaceutical company is selling all shares in the offering and is developing Haduvio (oral nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough.
The company also expects to grant underwriters a 30-day option to purchase up to an additional
$22.5 million in shares at the public offering price, less underwriting discounts and commissions.
Morgan Stanley, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers, with Oppenheimer & Co. serving as lead manager.
$TRVI $MS